NCT01650194View on ClinicalTrials.gov

A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 9, 2012

Primary Completion Date

January 4, 2018

Study Completion Date

January 4, 2018

Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
DRUG

enzalutamide

Participants received 160 mg of enzalutamide orally once daily (4 capsules, 40 mg each).

DRUG

abiraterone acetate

Participants received 1000 mg of abiraterone acetate orally once daily (4 tablets, 250 mg each).

DRUG

prednisone

Participants received 5 mg of prednisone orally twice daily (2 tablets, 5 mg each).

Trial Locations (1)

77030

Site US2492 MD Anderson Cancer Ctr, Houston

All Listed Sponsors
collaborator

Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

INDUSTRY

lead

Astellas Pharma Global Development, Inc.

INDUSTRY

NCT01650194 - A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients | Biotech Hunter | Biotech Hunter